An Observational Post-Authorization Safety Specialist Cohort Event Monitoring Study (SCEM) to Monitor the Safety and Utilization of Rivaroxaban (Xarelto®).

CompletedOBSERVATIONAL

Enrollment

3,400

Participants

Timeline

Start Date

May 31, 2013

Primary Completion Date

January 31, 2016

Study Completion Date

September 30, 2017

Conditions

Atrial FibrillationDeep Vein ThrombosisPulmonary Embolism

Trial Locations (1)

Drug Safety Research Unit, Southampton